How Big Is The Upside On These Stocks? UTi Worldwide Inc (UTIW) and Repros Therapeutics Inc (RPRX)

Posted by Saimoon April 3, 2015 0 Comment 826 views


New York, NY – GDP INSIDER  –  04/03/2015.

This article discusses two companies: UTi Worldwide Inc (NASDAQ:UTIW) and Repros Therapeutics Inc (NASDAQ:RPRX)

UTi Worldwide Inc (NASDAQ:UTIW) continued to fall yesterday with the stock losing another 3.31% or $0.33 to close down at $9.65 on higher than average trading volume of just over four million shares. The international non asset based supply chain services company has lost 24.01% of its value over the last five days, after it released disappointing fourth quarter and full year results on Wednesday. The company completely missed the market consensus earnings per share estimate of a loss of $0.08 by reporting a whopping $1.02 loss per share. Revenue was correspondingly down with UTi Worldwide Inc only generating $964.6 million compared to estimates of $1.08 billion. The company laid out a mixed forecast for this year, announcing a new strategic direction for its freight forwarding business, while tempering that with a reduced earnings estimate of only $125-150 million compared to its previous $190-210 million estimate. However, with RSI now at 19.79 it has buy potential.

 Is UTi Worldwide Inc Undervalued? Review The Technical Indicators With Free UTIW Analysis.

Repros Therapeutics Inc (NASDAQ:RPRX) reversed its recent decline yesterday with the stock gaining 4.59% or $0.39 to close at $8.88 with more than 2.009 million shares changing hands, compared to its three month average trading volume of just 0.304 million. The developer of small molecule drugs to treat reproductive disorders has been trading with the range of $7.60 and $9.97 for the last three months and does not seem able to get past its current resistance level of $10. However, the gains yesterday came after Repros Therapeutics Inc announced that its new drug application for its enclomiphene citrate based drug to treat hypogonadism in overweight men had been accepted for review by the Food and Drug Administration.  Repros Therapeutics Inc has a number of drugs in its pipeline, any of which could boost its share price if they complete testing and approval. With the stock still down 10.92% this year, there is medium term investment potential.

Can Repros Therapeutics Inc Provide Good Medium To Long Term Gains? Click Here For Free RPRX Analysis.

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment